Table 1 Characteristics of patients in the high-dose group and the comparison group at inclusion and at the moment of eligibility for high-dose etanercept
At inclusion | At eligibility for etanercept dose increase | |||||
|---|---|---|---|---|---|---|
High-dose ETN group (n = 32) | Comparison group (n = 11) | p | High-dose ETN group (n = 32) | Comparison group (n = 11) | p | |
Time from inclusion in months, median (IQR) | 0 | 0 | – | 10 (7–16) | 10 (7–15) | 0.98 |
Age, median (IQR) | 6 (4–10) | 8 (6–9) | 0.61 | – | – | |
Female, n (%) | 22 (69) | 8 (73) | 1.00 | – | – | |
JADAS-10, median (IQR) | 18 (15–22) | 20 (17–22) | 0.36 | 7 (4–10) | 9 (2–10) | 0.92 |
VAS patient/parent, median (IQR) | 63 (50–74) | 66 (37–75) | 0.94 | 39 (11–56) | 38 (6–61) | 1.00 |
VAS physician, median (IQR) | 51 (41–58) | 47 (40–65) | 0.92 | 12 (2–18) | 16 (8–31) | 0.50 |
Number of active joints, median (IQR) | 7 (5–11) | 11 (8–18) | 0.022 | 2 (0–4) | 2 (1–2) | 0.89 |
ESR in mm/hour, median (IQR) | 9 (5–25) | 8 (2–19) | 0.65 | 6 (2–9) | 7 (4–14) | 0.54 |
VAS pain, median (IQR) | 63 (49–72) | 69 (54–80) | 0.37 | 36 (9–62) | 22 (6–68) | 0.79 |
CHAQ, median (IQR) | 1.07 (0.75–1.63) | 1.50 (0.63–1.88) | 0.39 | 0.63 (0.38–1.25) | 0.69 (0.00–1.75) | 0.99 |